The Ontario Securities Commission (OSC) has issued an order recognizing that Acerus Pharmaceuticals Corporation (the Applicant) has ceased to offer its securities to the public. This decision is based on subsection 1(6) of the Business Corporations Act (Ontario) (OBCA). The Applicant, an offering corporation as defined by the OBCA, has its registered and head office in Toronto, Ontario.
The Applicant has stated that it does not plan to seek public financing through securities offerings. Furthermore, on August 25, 2023, the Applicant received an order confirming that it is not a reporting issuer in Ontario or any other Canadian jurisdiction, as per National Policy 11-206. The Applicant maintains that the conditions of the Reporting Issuer Order are still accurate.
The OSC, having determined that granting the order would not adversely affect the public interest, has ordered that the Applicant is deemed to have ceased to be offering its securities to the public as of September 20, 2023.